Carisma Therapeutics receives Nasdaq deficiency notice for market value below $50M

Carisma Therapeutics Inc.

Nasdaq notified Carisma on Oct 10, 2024 that MVLS fell below $50M minimum requirement.
Company has 180 days, until April 8, 2025, to regain compliance by closing at $50M+ for 10 consecutive days.
Failure to regain compliance may lead to delisting; company can appeal to a Nasdaq Hearing Panel.
Carisma will monitor MVLS and evaluate options to meet Nasdaq listing standards.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.